Diaceutics

A grant from the UK's East Midlands Development Agency will facilitate the search for a biomarker to personalize Astrimmune's pancreatic cancer vaccine.

According to the partners, the software, which is based on Diaceutics Fusion platform, will help commercial companies build biomarker hypotheses, request expressions of interest, and prepare proposals for clinical development.

The new software, which the firms plan to launch next year, is based on the Diaceutics Fusion platform, a personalized medicine planning application designed for targeted therapy development teams, and the London Genetics Biomarker Pathway platform.

The software, which is anticipated to be launched next year, will allow research teams to build biomarker hypotheses, request expressions of interest and prepare proposals for clinical development.

Pages

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.